Lyell Immunopharma (NASDAQ:LYEL) Trading Down 4.6%

Shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL) were down 4.6% during trading on Thursday . The stock traded as low as $2.26 and last traded at $2.27. Approximately 59,999 shares changed hands during trading, a decline of 94% from the average daily volume of 1,001,889 shares. The stock had previously closed at $2.38.

Analysts Set New Price Targets

Separately, HC Wainwright reduced their target price on shares of Lyell Immunopharma from $8.00 to $6.00 and set a “buy” rating for the company in a report on Thursday, February 29th.

Lyell Immunopharma Stock Performance

The stock has a market cap of $602.22 million, a P/E ratio of -2.56 and a beta of -0.56. The stock’s fifty day simple moving average is $2.26 and its 200-day simple moving average is $2.00.

Lyell Immunopharma (NASDAQ:LYEL) last posted its quarterly earnings data on Wednesday, February 28th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.01. The firm had revenue of $0.01 million during the quarter, compared to the consensus estimate of $4.96 million. Lyell Immunopharma had a negative net margin of 180,486.14% and a negative return on equity of 32.67%. As a group, equities research analysts forecast that Lyell Immunopharma, Inc. will post -0.81 earnings per share for the current year.

Institutional Trading of Lyell Immunopharma

A number of institutional investors have recently bought and sold shares of the business. Royal Bank of Canada lifted its holdings in shares of Lyell Immunopharma by 76.1% during the 1st quarter. Royal Bank of Canada now owns 9,114 shares of the company’s stock worth $46,000 after acquiring an additional 3,940 shares during the period. Principal Financial Group Inc. increased its position in Lyell Immunopharma by 11.8% during the 1st quarter. Principal Financial Group Inc. now owns 54,625 shares of the company’s stock worth $129,000 after purchasing an additional 5,767 shares in the last quarter. Wells Fargo & Company MN increased its position in Lyell Immunopharma by 5.2% during the 2nd quarter. Wells Fargo & Company MN now owns 120,724 shares of the company’s stock worth $384,000 after purchasing an additional 5,919 shares in the last quarter. Baillie Gifford & Co. increased its position in Lyell Immunopharma by 0.8% during the 4th quarter. Baillie Gifford & Co. now owns 761,321 shares of the company’s stock worth $2,642,000 after purchasing an additional 6,216 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its position in Lyell Immunopharma by 0.6% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 1,139,474 shares of the company’s stock worth $2,689,000 after purchasing an additional 6,618 shares in the last quarter. Institutional investors own 66.05% of the company’s stock.

About Lyell Immunopharma

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.